(Yicai Global) May 10 -- China's BGI Genomics Co., one of the world’s genome sequencing centers, will partner with a well-known traditional Chinese medicine firm to conduct basic research and application of diagnosis and treatment of anorectal and lower digestive tract diseases through gene sequencing to build Chinese anorectal metadatabase.
Shenzhen-based BGI Genomics and Mayinglong Pharmaceutical Group Co., which is headquartered in Wuhan, capital of central Hubei province, signed a cooperation agreement yesterday, both companies said.
Per the agreement, the pair will use gene sequencing as a carrier to achieve early screening and diagnosis of diseases such as colorectal cancer, inflammatory bowel disease and irritable bowel syndrome.
Mayinglong Pharmaceutical is a well-known Chinese TCM firm with a history of more than 400 years. The company's medicines are said to have a good effect in the treatment of anorectal diseases.
The two sides will also use genomics as a carrier to carry out basic research and application of intestinal microflora to promote its application in anorectal and lower digestive tract health care, disease screening, diagnosis and treatment and rehabilitation care.
They will also use metagenomics, which refers to the study of genetic material recovered directly from environmental samples, big data research, combined with clinical phenotypic data, to jointly build Chinese anorectal metadatabase.
The partnership will help promote the application of genomics in anorectal health field, accelerate the development of gene technology in the sector and provide a professional, personalized and diversified anorectal health management for patients, both companies added.
Editor: Mevlut Katik